ImmuPharma plc (LON:IMM – Get Free Report)’s stock price traded down 11.2% on Thursday . The company traded as low as GBX 3.82 ($0.05) and last traded at GBX 3.82 ($0.05). 13,132,889 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 19,740,949 shares. The stock had previously closed at GBX 4.31 ($0.05).
ImmuPharma Trading Up 2.6 %
The stock’s fifty day moving average is GBX 2.77 and its two-hundred day moving average is GBX 2.04. The company has a market capitalization of £16.58 million, a PE ratio of -6.74 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Roblox’s Big Dip: A Chance to Get in on the Vaunted Gaming Stock?
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Dividend ETFs to Capitalize on the Slide in Chip Stocks
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Is Chevron Stock Primed for Growth After Profit-Boosting News?
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
